125 related articles for article (PubMed ID: 1839014)
1. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
2. [Plasma concentrations of non-esterified fatty acids and lipids in high-dose medroxyprogesterone therapy of metastatic breast cancer].
Hofmann M; Holzer A; Brockerhoff P; Rathgen GH
Zentralbl Gynakol; 1993; 115(11):495-9. PubMed ID: 8296495
[TBL] [Abstract][Full Text] [Related]
3. Medroxyprogesterone acetate and lipid metabolic changes.
Teichmann AT; Wander HE; Cremer P; Wieland H; Kuhn W; Nagel GA; Seidel D
Arzneimittelforschung; 1987 May; 37(5):573-7. PubMed ID: 2956958
[TBL] [Abstract][Full Text] [Related]
4. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
5. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
6. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
[TBL] [Abstract][Full Text] [Related]
7. [Changes in serum lipoproteins under hormonal therapy of breast carcinoma and other endocrine-dependent tumors].
Wander HE; Teichmann AT; Cremer P; Wieland H; Kruse B; Nagel GA; Kuhn W; Seidel D
Onkologie; 1985 Apr; 8(2):88-92. PubMed ID: 3158861
[TBL] [Abstract][Full Text] [Related]
8. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
[TBL] [Abstract][Full Text] [Related]
9. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
10. Medroxyprogesterone acetate at very high doses in postmenopausal advanced breast cancer patients.
Pannuti F; Longhi A; Martoni A; Piana E; Baroni M
Chemioterapia; 1987 Dec; 6(6):396-8. PubMed ID: 2963702
[TBL] [Abstract][Full Text] [Related]
11. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
[TBL] [Abstract][Full Text] [Related]
12. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
13. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
14. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system].
Schenk H; Fereberger W
MMW Munch Med Wochenschr; 1983 Oct; 125(40):875-6. PubMed ID: 6226871
[No Abstract] [Full Text] [Related]
15. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
17. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
19. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
20. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
